| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.03 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.062 | 0.03 |
| mRNA | phenformin | GDSC1000 | pan-cancer | AAC | 0.067 | 0.03 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.074 | 0.03 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.04 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | 0.1 | 0.04 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.059 | 0.04 |